CACA guidelines for holistic integrative management of adult acute myeloid leukemia

Hui Wei, Yingchang Mi, Ying Wang, Erlie Jiang, Jianda Hu, Xiaojing Yan, Yanqiu Han, Yongrong Lai, Yong You, Sujun Gao, Chunji Gao, Bing Xu, Wenjuan Yu, Jieping Chen, Suning Chen, Tiejun Gong, Linhua Yang, Jianmin Yang, Xin Du, Wei Li, Li Fei, Yan Li, Li J, Junmin Li, Jie Jin, Xi Zhang, Mei Zhang, Yu Zhang, Guangsen Zhang, Xianmin Song, Yongping Song, Qian Jiang, Tong Wu, Ting Liu, Zhuogang Liu, Dai‐Hong Liu, Hanyun Ren, Ru Feng, Rong Fu, Hong‐Hu Zhu, Zimin Sun, Jianmin Wang, Xin Wang, Jishi Wang, Shaoyuan Wang, Meiyun Fang, He Huang, Yu Hu, Qifa Liu, Jun Ma, Zhixiang Shen, Depei Wu, Xiao‐Jun Huang, Jianfeng Zhou, Chunyan Ji, Lugui Qiu, Jianyong Li, Jianxiang WangHolistic 2024 · DOI

Abstract

The CACA Guidelines, summarized by the Hematology Oncology Committee of the China Anti-Cancer Association, provide a comprehensive framework for the management of adult acute myeloid leukemia (AML). These guidelines address diagnosis and treatment options for both younger (age < 60 years) and older (age ≥ 60 years) patients, including non-APL, APL, and relapsed/refractory (R/R) AML. A key feature is the emphasis on holistic integrative medicine, focusing on the management of complications such as central nervous system leukemia (CNSL), cardiotoxicity, infection, and nursing care to enhance both treatment efficacy and patient quality of life.

Introduction

Acute Myeloid Leukemia (AML) is a highly heterogeneous hematologic malignancy where standardized treatment often fails to address individual biological complexities. The CACA guidelines advocate for a "holistic integrative" approach that spans the entire patient journey—from molecular diagnosis and age-stratified treatment to the aggressive management of complications. By integrating molecular oncology with supportive care, these guidelines aim to reduce secondary mortality caused by treatment-related toxicities like fungal infections and cardiotoxicity.

Risk Stratification and Methodology

The guidelines synthesize expert consensus and evidence from international standards, such as the WHO 2016 classification. A cornerstone of this approach is Molecular Risk Stratification, which categorizes patients into "Good," "Moderate," and "Poor" prognosis groups based on cytogenetics and molecular markers.

Risk stratification based on cytogenetics and molecular genetics

This stratification allows clinicians to tailor therapeutic intensity. For instance, while a 20% blast cell count is the standard threshold for diagnosis, patients with specific recurrent cytogenetic abnormalities (e.g., $t(8;21)$ or $inv(16)$) are diagnosed with AML even with lower blast counts. Furthermore, the guidelines emphasize the use of Measurable Residual Disease (MRD) monitoring via PCR or flow cytometry to guide post-remission therapy; if a "Good" prognosis patient remains MRD-positive after consolidation, an escalation to hematopoietic stem cell transplantation (HSCT) is recommended.

Clinical Treatment Pathways

Treatment strategies are primarily divided by patient age and fitness. For younger patients (<60 years), intensive induction remains the standard, while older patients (≥60 years) often require lower-intensity regimens focused on quality of life.

Classification of chemotherapy regimens for AML induction

Key Therapeutic Strategies:

  • Younger Patients: Standard induction typically involves the "7+3" regimen (Ara-C + Ida/Dnr). Post-remission options include high-dose Ara-C or HSCT based on the risk profile.
  • Older Patients: For those unfit for intensive chemotherapy, the combination of Venetoclax with Azacitidine or Decitabine is the preferred low-intensity option.
  • Acute Promyelocytic Leukemia (APL): This subset is treated with highly effective "chemo-free" approaches using ATRA and Arsenic Trioxide.
  • Relapsed/Refractory (R/R) AML: The guidelines strongly recommend clinical trial participation or targeted therapies, such as Gilteritinib for patients with FLT3 mutations.

Holistic Integrative Care

A significant portion of the CACA guidelines is dedicated to managing complications. Recognizing the prevalence of Hepatitis B in certain regions, the guidelines mandate prophylactic antivirals like Entecavir to prevent HBV reactivation during chemotherapy. Additionally, to combat the irreversible cardiotoxicity of anthracyclines, early monitoring and the use of cardioprotective agents (e.g., ACE inhibitors, Coenzyme Q10) are established as standard supportive care.

Conclusion

The CACA guidelines provide a unified clinical standard that balances aggressive anti-leukemic therapy with comprehensive supportive care. While the "holistic" model requires significant infrastructure for MRD testing and infection control, it represents a vital shift toward personalized, integrative oncology. Future updates will be necessary as novel targeted inhibitors, such as Menin or IDH inhibitors, continue to evolve the therapeutic landscape.

Summary updated

Abstract

Abstract The CACA Guidelines was summarized by Hematology Oncology Committee of China Anti- Cancer Association. This portion of the CACA Guidelines for adult acute myeloid leukemia (AML) not only focuses on diagnosis, the treatment options for younger (age &lt; 60 years) and older (age ≥ 60 years) patients (including non-APL, APL, R/R AML), but also pay attention to the treatment of AML complications, including central nervous system leukemia (CNSL), cardiotoxicity, agranulocytosis and fever, hepatitis B virus reactivation, uric acid nephropathy, bleeding and coagulation disorders, and nursing for patients with AML from the perspective of holistic integrative medicine to enhance the quality of life and treatment effects.
BibTeX
@inproceedings{wei2024caca,
  author = {Hui Wei and Yingchang Mi and Ying Wang and Erlie Jiang and Jianda Hu and Xiaojing Yan and Yanqiu Han and Yongrong Lai and Yong You and Sujun Gao and Chunji Gao and Bing Xu and Wenjuan Yu and Jieping Chen and Suning Chen and Tiejun Gong and Linhua Yang and Jianmin Yang and Xin Du and Xin Du and Wei Li and Li Fei and Yan Li and Li J and Junmin Li and Jie Jin and Xi Zhang and Mei Zhang and Yu Zhang and Guangsen Zhang and Xianmin Song and Yongping Song and Qian Jiang and Tong Wu and Ting Liu and Zhuogang Liu and Dai‐Hong Liu and Hanyun Ren and Ru Feng and Rong Fu and Hong‐Hu Zhu and Zimin Sun and Jianmin Wang and Xin Wang and Jishi Wang and Shaoyuan Wang and Meiyun Fang and He Huang and Yu Hu and Qifa Liu and Jun Ma and Zhixiang Shen and Depei Wu and Xiao‐Jun Huang and Jianfeng Zhou and Chunyan Ji and Lugui Qiu and Jianyong Li and Jianxiang Wang},
  title = {{CACA guidelines for holistic integrative management of adult acute myeloid leukemia}},
  booktitle = {Holistic},
  year = {2024},
  doi = {10.1007/s44178-024-00078-9},
}
Figure